
FDA approved Novartis’ secukinumab (Cosentyx) 150 mg for adults with polymyalgia rheumatica who respond inadequately to corticosteroids or cannot tolerate a taper. In the Phase 3 REPLENISH trial, secukinumab doubled sustained remission rates.
RCA opens a new office in Warsaw, Poland.
Regulatory Compliance Associates
(RCA), a life-sciences consulting firm, has expanded into Europe with a new office in Warsaw, Poland.
RCA is headquartered in the US with offices in Pleasant Prairie, WI and Tampa, FL. According to the company, RCA choose Warsaw as its next location, because of its proximity to other central eastern european biotech industries.
Source:
Regulatory Compliance Associates






